Finished medical devices company Freudenberg Medical has added two new haemostasis valves, HyperSeal and CertuSeal, to its existing FlexSeal valve.
The haemostasis valves are designed to reduce blood loss and enable minimally invasive medical procedures that involve the use of catheters.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Through the new valves, the firm intends to offer new design options and minimise development time and costs by facilitating direct integration into therapeutic catheter development.
The valves are expected to cater to medical device firms seeking rapid time to market.
Freudenberg Medical Portfolio Management director Bernie Kaeferlein said: “Freudenberg Medical’s haemostasis valves provide a wide range of innovative features designed to greatly improve haemostasis and procedural performance when integrated into next-generation catheters and delivery systems.
“As a partner for innovation, we are committed to proactively addressing unmet clinical needs and offering our medical device customers a growing portfolio of finished device, design, and process solutions to help improve efficiency and accelerate their time to market.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe firm has also released a new white label device solution, HyperSeal Introducer Sheath, which has a hydrophilic coating for large bore procedures.
Freudenberg Medical acts as a partner for the design, development and manufacture of medical devices, components and product solutions.
The firm operates 11 manufacturing facilities with more than 1,500 employees.
In addition to finished devices, Freudenberg provides subassemblies for minimally invasive, handheld and catheter-based devices, thermoplastic components and tubing to drug coatings.
